Terconazole vaginal cream, 0.8% is indicated for the treatment of vulvovaginal candidiasis.

{ "type": "p", "children": [], "text": "Terconazole vaginal cream, 0.8% is indicated for the treatment of vulvovaginal candidiasis." }

The recommended dose is one applicator full of terconazole vaginal cream 0.8% (5 grams of cream containing 40 mg terconazole) administered intravaginally once daily at bedtime for three consecutive days [see Patient Counseling Information (17.1)]. Terconazole vaginal cream, 0.8% is not for oral or ophthalmic use.

{ "type": "p", "children": [], "text": "The recommended dose is one applicator full of terconazole vaginal cream 0.8% (5 grams of cream containing 40 mg terconazole) administered intravaginally once daily at bedtime for three consecutive days [see Patient Counseling Information (17.1)]. Terconazole vaginal cream, 0.8% is not for oral or ophthalmic use. " }

Terconazole vaginal cream, 0.8% contains 8mg terconazole per gram of cream. Each measured dose applicator delivers 5 grams of cream containing 40 mg of terconazole.

{ "type": "p", "children": [], "text": "Terconazole vaginal cream, 0.8% contains 8mg terconazole per gram of cream. Each measured dose applicator delivers 5 grams of cream containing 40 mg of terconazole." }

Terconazole vaginal cream, 0.8% is contraindicated in patients with known hypersensitivity to terconazole or to any of the components of the cream.

{ "type": "p", "children": [], "text": "Terconazole vaginal cream, 0.8% is contraindicated in patients with known hypersensitivity to terconazole or to any of the components of the cream." }

There is no information regarding cross-hypersensitivity between terconazole and other azole antifungal agents. Monitor patients with a history of hypersensitivity to azoles.

{ "type": "p", "children": [], "text": "There is no information regarding cross-hypersensitivity between terconazole and other azole antifungal agents. Monitor patients with a history of hypersensitivity to azoles." }

Discontinue use and do not retreat with terconazole if irritation, fever, chills or flulike symptoms are reported during use.

{ "type": "p", "children": [], "text": "Discontinue use and do not retreat with terconazole if irritation, fever, chills or flulike symptoms are reported during use." }

During controlled clinical studies conducted in the United States, patients with vulvovaginal candidiasis were treated with terconazole vaginal cream, 0.8% for 3 days. Based on comparative analyses with placebo (Table 1), the adverse experiences considered most likely related to terconazole vaginal cream, 0.8% were headache (21% vs. 16% with placebo) and dysmenorrhea (6% vs. 2% with placebo). Other adverse experiences reported with terconazole vaginal cream 0.8% were abdominal pain (3.4% vs. 1% with placebo), fever (1% vs. 0.3% with placebo), and genital burning and itching (5% vs. 6%-9% with placebo). The therapy-related dropout rate was 2.0% for terconazole vaginal cream 0.8%. The adverse drug experience most frequently causing discontinuation of terconazole vaginal cream, 0.8% therapy was vulvovaginal itching (0.7% vs. 0.3% placebo).

Table 1

<div class="scrollingtable"><table width="100%"> <col width="30%"/> <col width="36%"/> <col width="33%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Adverse Reactions Most Likely Related to Terconazole Vaginal Cream, 0.8%</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"></td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terconazole Vaginal Cream, 0.8%</span> </p> <p> <span class="Bold">n=231 (%)</span> </p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terazol<span class="Sup">®</span>3 (Placebo)</span> </p> <p> <span class="Bold">n=229 (%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Headache</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">49 (21)</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">37(16)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dysmenorrhea</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">14 (6)</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">5 (2)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Other Adverse Events Reported with Terconazole Vaginal Cream 0.8%</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"></td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terconazole Vaginal Cream 0.8%</span> </p> <p> <span class="Bold">n=231 (%)</span> </p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terazol<span class="Sup">®</span>3</span> </p> <p> <span class="Bold"> n=229 (%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abdominal Pain</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">8 (3.4)</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">2 (1)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fever</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">2 (1)</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">1 (0.3)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Genital Burning and Itching</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">12 (5)</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">15-21 (6-9)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Adverse Events Most Frequently Causing Discontinuation</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"></td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terconazole Vaginal Cream 0.8%</span> </p> <p> <span class="Bold">n=231 (%)</span> </p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terazol<span class="Sup">®</span>3</span> </p> <p> <span class="Bold"> n=229 (%)</span> </p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">Vulvovaginal Itching</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">2 (0.7)</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">1 (0.3)</p> </td> </tr> </tbody> </table></div>

Photosensitivity reactions were observed in some normal volunteers following repeated dermal application of terconazole 2.0% and 0.8% creams under conditions of filtered artificial ultraviolet light. Photosensitivity reactions were not observed in U.S. and foreign clinical trials in patients who were treated with terconazole suppositories or vaginal cream, 0.8%.

Oral Contraceptives: There is no known interaction with the concomitant use of this product and oral contraceptives.

{ "type": "p", "children": [], "text": "Oral Contraceptives: There is no known interaction with the concomitant use of this product and oral contraceptives." }

Terconazole vaginal cream, 0.8% should not be used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. There are no adequate and well-controlled clinical trials of terconazole vaginal cream, 0.8% in pregnant women.

Animal data

There was no evidence of teratogenicity when terconazole was administered orally up to (10 times the recommended intravaginal human dose based on body surface area comparisons) in rats, or rabbits.

There was a delay in fetal ossification at 10 mg/kg/day in rats (about 2 times the recommended intravaginal human dose based on body surface area comparisons). Higher doses, up to 10 times the recommended intravaginal human dose based on body surface area comparisons, resulted in decreased litter size, decreased number of viable young and reduced fetal weight in rats. There was also delay in ossification and an increase incidence of skeletal variants.

The dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats of 0.176 mcg/mL which exceeds by 30 times the mean peak plasma level (0.006 mcg/mL) seen in normal subjects after intravaginal administration of terconazole vaginal cream 0.8%. This safety assessment does not account for possible exposure of the fetus through direct transfer to terconazole from the irritated vagina by diffusion across amniotic membranes. Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus.

It is not known whether terconazole is excreted in human milk. Caution should be exercised when terconazole is administered to a nursing woman.

The safety and effectiveness of terconazole vaginal cream, 0.8% have not been established in pre-menarchal females.

Clinical studies of terconazole vaginal cream, 0.8% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Overdosage of terconazole in humans has not been reported to date.

{ "type": "p", "children": [], "text": "Overdosage of terconazole in humans has not been reported to date." }

Terconazole vaginal cream 0.8% is a white to off-white, water washable cream for intravaginal administration containing 0.8% of the antifungal agent terconazole, cis-1-[p[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4- yl]methoxy]phenyl]-4-isopropylpiperazine, compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, stearyl alcohol, and purified water. The structural formula of terconazole is as follows:

{ "type": "p", "children": [], "text": "Terconazole vaginal cream 0.8% is a white to off-white, water washable cream for intravaginal administration containing 0.8% of the antifungal agent terconazole, cis-1-[p[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4- yl]methoxy]phenyl]-4-isopropylpiperazine, compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, stearyl alcohol, and purified water. The structural formula of terconazole is as follows:" }

Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol.

{ "type": "p", "children": [], "text": "Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol. " }

Terconazole is an antifungal agent [see Clinical Pharmacology, Microbiology (12.4)].

Following intravaginal administration of terconazole vaginal cream, 0.8% in females, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations.

Following daily intravaginal administration of 0.8% terconazole 40 mg (0.8% cream x 5 g) for seven days to healthy female subjects, plasma concentrations were low and gradually rose to a daily peak (mean of 5.9 ng/mL or 0.006 mcg/mL) at 6.6 hours. Results from similar studies in female patients with vulvovaginal candidiasis indicate that the slow rate of absorption, the lack of accumulation, and the mean peak plasma concentration of terconazole was not different from that observed in healthy females. The absorption characteristics of terconazole vaginal cream, 0.8% in pregnant or non-pregnant patients with vulvovaginal candidiasis were also similar to those found in healthy subjects.

Following oral (30 mg) administration of 14C-labelled terconazole, the mean half-life of elimination from the blood for the parent terconazole was 6.9 hours (range 4.0-11.3). Terconazole is extensively metabolized; the plasma AUC for terconazole compared to the AUC for total radioactivity was 0.6%. Total radioactivity was eliminated from the blood with a mean elimination half-life of 52.2 hours (range 44-60). Excretion of radioactivity was both by renal (32-56%) and fecal (47- 52%) routes.

In vitro, terconazole is highly protein bound (94.9%) and the degree of binding is independent of drug concentration.

Mechanism of Action

Terconazole inhibits the enzyme cytochrome P450 14α-demethylase which leads to inhibition of ergosterol synthesis, an essential component of the fungal cell membrane

Activity in vitro

Terconazole exhibits fungicidal activity in vitro against Candida albicans.

Drug Resistance

Studies showed no development of resistance to terconazole during successive passages of C. albicans. However, the clinical significance of such an effect is not known.

Studies to determine the carcinogenic potential of terconazole have not been performed. Terconazole was not mutagenic when tested in vitro for induction of microbial point mutations (Ames test), or for inducing cellular transformation, or in vivo for chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells. No impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day (about 10 times the recommended intravaginal human dose based on body surface area comparisons) for a three-month period.

The efficacy of terconazole vaginal cream, 0.8% in the treatment of vulvovaginal candidiasis in adult women was evaluated in a multicenter, randomized, double-blind, controlled non-inferiority trial comparing terconazole vaginal cream, 0.8% for 3 days (n =231) to another preparation of terconazole vaginal cream 0.8% active comparator for 3 days (n=229). The modified intent-to-treat population (randomized patients who received treatment and had a positive baseline culture for Candida) consisted of 140 terconazole vaginal cream, 0.8% patients and 153 active comparator patients. Therapeutic cure defined as clinical and mycological cure was assessed at Visit 3 (Day 21-30). Table 2 shows the therapeutic, clinical and mycological cure rates in this trial. The therapeutic cure rate at Visit 3 was 67.1% for the terconazole group and 52.3% for the active comparator group (95% confidence interval about the 14.8% difference in therapeutic cure rate: 3.0% to 26.6%).

{ "type": "p", "children": [], "text": "The efficacy of terconazole vaginal cream, 0.8% in the treatment of vulvovaginal candidiasis in adult women was evaluated in a multicenter, randomized, double-blind, controlled non-inferiority trial comparing terconazole vaginal cream, 0.8% for 3 days (n =231) to another preparation of terconazole vaginal cream 0.8% active comparator for 3 days (n=229). The modified intent-to-treat population (randomized patients who received treatment and had a positive baseline culture for Candida) consisted of 140 terconazole vaginal cream, 0.8% patients and 153 active comparator patients. Therapeutic cure defined as clinical and mycological cure was assessed at Visit 3 (Day 21-30). Table 2 shows the therapeutic, clinical and mycological cure rates in this trial. The therapeutic cure rate at Visit 3 was 67.1% for the terconazole group and 52.3% for the active comparator group (95% confidence interval about the 14.8% difference in therapeutic cure rate: 3.0% to 26.6%)." }

Table 2: Efficacy of Terconazole Vaginal Cream 0.8% for the Treatment of Vulvovaginal Candidiasis in a Randomized, Double-Blind Active Controlled Study*

{ "type": "p", "children": [], "text": "\nTable 2: Efficacy of Terconazole Vaginal Cream 0.8% for the Treatment of Vulvovaginal Candidiasis in a Randomized, Double-Blind Active Controlled Study*\n" }

<div class="scrollingtable"><table width="100%"> <col width="22%"/> <col width="21%"/> <col width="21%"/> <col width="29%"/> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Outcome</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Terconazole Vaginal Cream 0.8%</span> </p> <p> <span class="Bold">n=140 (%)</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Active Control</span> </p> <p> <span class="Bold">n=153</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Treatment Difference (%) [95% Confidence Interval]</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"></td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">% Cure</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">% Cure</p> </td><td class="Botrule Lrule Rrule Toprule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Therapeutic Cure</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">67.1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">52.3</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">14.8 [3.0, 26.6]</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Clinical Cure</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">79.3</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">66.0</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">13.3 [2.5, 24.0]</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">Mycological Cure</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">70.7</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">56.9</p> </td><td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">13.8 [2.2, 25.4]</p> </td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"100%\">\n<col width=\"22%\"/>\n<col width=\"21%\"/>\n<col width=\"21%\"/>\n<col width=\"29%\"/>\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">\n<span class=\"Bold\">Outcome</span>\n</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">\n<span class=\"Bold\">Terconazole Vaginal Cream 0.8%</span>\n</p>\n<p>\n<span class=\"Bold\">n=140 (%)</span>\n</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">\n<span class=\"Bold\">Active Control</span>\n</p>\n<p>\n<span class=\"Bold\">n=153</span>\n</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">\n<span class=\"Bold\">Treatment Difference (%) [95% Confidence Interval]</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">% Cure</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">% Cure</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\" valign=\"top\">\n<p class=\"First\">Therapeutic Cure</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">67.1</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">52.3</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">14.8 [3.0, 26.6]</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule\" valign=\"top\">\n<p class=\"First\">Clinical Cure</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">79.3</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">66.0</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">13.3 [2.5, 24.0]</p>\n</td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">Mycological Cure</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">70.7</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">56.9</p>\n</td><td align=\"center\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">13.8 [2.2, 25.4]</p>\n</td>\n</tr>\n</tbody>\n</table></div>" }

* Modified intent-to-treat population

{ "type": "p", "children": [], "text": "* Modified intent-to-treat population" }

Terconazole Vaginal Cream 0.8% is supplied in 20 gram tubes with a measured dose applicator.

{ "type": "p", "children": [], "text": "Terconazole Vaginal Cream 0.8% is supplied in 20 gram tubes with a measured dose applicator." }

NDC 0168-0347-20

{ "type": "p", "children": [], "text": "NDC 0168-0347-20" }

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

{ "type": "p", "children": [], "text": "Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]." }

Patients using terconazole vaginal cream, 0.8% should receive the following information and instructions:

Patients prone to vaginal yeast infections should receive the following instructions:

PATIENT INFORMATION

TERCONAZOLE

(ter kon ah zol)

VAGINAL CREAM, 0.8%

<div class="scrollingtable"><table width="100%"> <col width="93%"/> <tbody class="Headless"> <tr class="First Last"> <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Important: For use in the vagina only. Terconazole vaginal cream, 0.8% is not for use in the mouth, eyes or inside the nose.</span> </p> </td> </tr> </tbody> </table></div>

Read the Patient Information that comes with terconazole vaginal cream, 0.8% before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment.

What is terconazole vaginal cream, 0.8%?

Terconazole vaginal cream, 0.8% is prescription medicine used to treat vaginal yeast infections caused by a fungus called Candida (KAN di duh).

It is not known if terconazole vaginal cream, 0.8% is safe or effective in females who have not reached puberty.

Who should not use terconazole vaginal cream, 0.8%?

Do not use terconazole vaginal cream, 0.8% if you are allergic to terconazole or any of the other ingredients of the cream. See the end of this leaflet for a complete list of ingredients in terconazole vaginal cream, 0.8%.

What should I tell my doctor before using terconazole vaginal cream, 0.8%?

Before using terconazole vaginal cream, 0.8%, tell your doctor if you:

Tell your doctor about all the medicines that you take including prescription and non-prescription medicines, vitamins and herbal supplements. Certain types of medicines can increase the chance of getting vaginal infections.

How should I use terconazole vaginal cream, 0.8%?

What are possible side effects with terconazole vaginal cream, 0.8%?

Tell your doctor if you get any of the following symptoms during treatment with terconazole vaginal cream, 0.8%:

If you have any of the symptoms listed above, your doctor may tell you to stop using terconazole vaginal cream, 0.8% and prescribe a different medicine to treat your fungal infection.

Common side effects of terconazole vaginal cream, 0.8% include

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of terconazole vaginal cream, 0.8%. Ask your doctor or pharmacist for more information.

Call your doctor for advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088

How should I store terconazole vaginal cream, 0.8%?

General information about terconazole vaginal cream, 0.8%

Medicines are sometimes prescribed for purposes other than those listed in patient information leaflet. Do not use terconazole vaginal cream, 0.8% for a condition for which it was not prescribed. Do not give terconazole vaginal cream, 0.8% to other people, even if they have the same symptoms you have. It may harm them.

This leaflet summarizes the most important information about terconazole vaginal cream, 0.8%. If you would like more information, talk with your doctor. You can also ask your pharmacist or doctor for information about terconazole vaginal cream, 0.8% that is written for healthcare professionals. If you have questions about terconazole vaginal cream, 0.8% you can also call: 1-800-645-9833.

What are the ingredients in terconazole vaginal cream, 0.8%?

<div class="scrollingtable"><table width="100%"> <col width="79%"/> <col width="21%"/> <tbody class="Headless"> <tr class="First Toprule"> <td valign="top"> <p class="First"> <span class="Bold">Instructions for Use</span> </p> <p> <span class="Bold">Terconazole Vaginal Cream, 0.8%</span> </p> <p>Be sure to read, understand, and follow the instructions below for how to use terconazole vaginal cream, 0.8% correctly.</p> <dl> <dt>1.</dt> <dd> <span class="Bold">Wash your hands.</span> </dd> <dt>2.</dt> <dd> <span class="Bold">Fill the Applicator:</span> </dd> <dt>•</dt> <dd>Remove the cap from the tube. </dd> <dt>•</dt> <dd>Use the pointed tip on the top of the cap to puncture the seal on the tube. </dd> <dt>•</dt> <dd>Screw the applicator onto the tube.</dd> <dt>•</dt> <dd>Squeeze the tube from the bottom and fill the applicator until the plunger stops.</dd> <dt>•</dt> <dd>Unscrew the applicator from the tube.</dd> </dl> </td><td valign="top"><a name="id1768801023"></a><img alt="fig-1" src="/dailymed/image.cfm?name=terconazole-03.jpg&amp;setid=f59448bd-f730-46d2-a785-c2d6205579ff"/><a name="id654265953"></a><img alt="fig-2" src="/dailymed/image.cfm?name=terconazole-04.jpg&amp;setid=f59448bd-f730-46d2-a785-c2d6205579ff"/></td> </tr> <tr> <td valign="top"> <dl> <dt>3.</dt> <dd> <span class="Bold">Insert the Cream:</span> </dd> <dt>•</dt> <dd>Lie on your back with knees drawn up toward your chest.</dd> <dt>•</dt> <dd>Holding the applicator by the ribbed end of the barrel, insert the filled applicator into the vagina as far as it will comfortably go.</dd> <dt>•</dt> <dd>Slowly press the plunger of the applicator to release the cream into the vagina.</dd> <dt>•</dt> <dd>Remove the applicator from the vagina. Wash the applicator.</dd> </dl> </td><td valign="top"><a name="id-1270540348"></a><img alt="fig-3" src="/dailymed/image.cfm?name=terconazole-05.jpg&amp;setid=f59448bd-f730-46d2-a785-c2d6205579ff"/></td> </tr> <tr class="Botrule Last"> <td valign="top"> <dl> <dt>4.</dt> <dd> <span class="Bold">Wash the Applicator after Use</span> </dd> <dt>•</dt> <dd>Wash the applicator after each use.</dd> <dt>•</dt> <dd>Pull the plunger out of the barrel.</dd> <dt>•</dt> <dd>Wash the applicator pieces with lukewarm, soapy water and then dry them thoroughly.</dd> <dt>•</dt> <dd>Put the dry applicator pieces back together by gently pushing the plunger into the barrel as far as it will go.</dd> <dt>5.</dt> <dd> <span class="Bold">Wash your hands well after you finish washing and drying the applicator.</span> </dd> </dl> <a name="id772515699"></a><img alt="mfg-stmnt" src="/dailymed/image.cfm?name=terconazole-07.jpg&amp;setid=f59448bd-f730-46d2-a785-c2d6205579ff"/></td><td valign="top"><a name="id2011945399"></a><img alt="fig-4" src="/dailymed/image.cfm?name=terconazole-06.jpg&amp;setid=f59448bd-f730-46d2-a785-c2d6205579ff"/></td> </tr> </tbody> </table></div>

The brands listed are the registered trademarks of their respective owners and are not trademarks of Fougera Pharmaceuticals Inc.

Revised: December 2024

46365073

#34

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 20 GRAM TUBE

{ "type": "p", "children": [], "text": "\n PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 20 GRAM TUBE \n" }

NDC 0168-0347-20

{ "type": "p", "children": [], "text": "\nNDC 0168-0347-20 " }

Rx only

{ "type": "p", "children": [], "text": "\nRx only\n" }

Terconazole Vaginal Cream 0.8%

{ "type": "p", "children": [], "text": "\nTerconazole Vaginal Cream 0.8%\n" }

For Vaginal Use Only

{ "type": "p", "children": [], "text": "\nFor Vaginal Use Only\n" }

Fougera ®

{ "type": "p", "children": [], "text": "\nFougera ®\n" }

Each gram contains: Butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60,

{ "type": "p", "children": [], "text": "Each gram contains: Butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60," }

polysorbate 80, propylene glycol, stearyl alcohol, and purified water.

{ "type": "p", "children": [], "text": "polysorbate 80, propylene glycol, stearyl alcohol, and purified water." }

NET WT 20 grams

{ "type": "p", "children": [], "text": "\nNET WT 20 grams\n" }

Quantity by weight not by volume

{ "type": "p", "children": [], "text": "Quantity by weight not by volume" }

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 20 GRAM CARTON

{ "type": "p", "children": [], "text": "\n PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 20 GRAM CARTON \n" }

NDC 0168-0347-20

{ "type": "p", "children": [], "text": "\nNDC 0168-0347-20 " }

Rx only

{ "type": "p", "children": [], "text": "\nRx only\n" }

Terconazole Vaginal Cream 0.8%

{ "type": "p", "children": [], "text": "\nTerconazole Vaginal Cream 0.8%\n" }

Tube and Applicator

{ "type": "p", "children": [], "text": "\nTube and Applicator\n" }

Fougera ®

{ "type": "p", "children": [], "text": "\nFougera ® \n" }

KEEP OUT OF THE REACH OF CHILDREN.

{ "type": "p", "children": [], "text": "\nKEEP OUT OF THE REACH OF CHILDREN. \n" }

NET WT 20 grams

{ "type": "p", "children": [], "text": "\nNET WT 20 grams \n" }